M. Fischer

Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti‐PLA2R positive primary membranous nephropathy

P. Brenchley, S. Mitra, P. Hamilton, 2018, Journal of clinical apheresis.

Lipoprotein apheresis downregulates IL-1α, IL-6 and TNF-α mRNA expression in severe dyslipidaemia.

G. Watts, C. Stefanutti, C. Morozzi, 2017, Atherosclerosis. Supplements.